Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Jessica KendrickMichel Chonchol

Abstract

Chronic kidney disease (CKD) is associated with an increased risk of incident cardiovascular disease (CVD); however, the role of statins for the primary prevention of acute cardiovascular events in patients with CKD and the effect of statins on kidney function loss in persons without prevalent CVD have not been studied. Post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Multicenter, randomized, double-blind, placebo-controlled trial of 5,608 men and 997 women without CVD randomly assigned to treatment with lovastatin or placebo. Placebo or lovastatin, 20 mg/d. First major acute cardiovascular event in participants with mild CKD and kidney function loss in persons with or without CKD. Estimated glomerular filtration rate was calculated using the 4-variable Modification of Diet in Renal Disease Study equation. At baseline, mean estimated glomerular filtration rate in participants with CKD (n = 304) was 53.0 +/- 6.0 mL/min/1.73 m(2). After an average follow-up of 5.3 +/- 0.8 years, the incidence of a fatal and nonfatal CVD event was lower in participants with CKD receiving lovastatin than in those receiving placebo (adjusted relative risk [RR], 0.31; 95% CI, 0.13-0.72; P = 0.01). Tests for interact...Continue Reading

References

Mar 1, 1990·Kidney International·B L KasiskeW F Keane
Aug 1, 1997·The American Journal of Cardiology·J R DownsA M Gotto
Jan 17, 2003·Annals of Internal Medicine·Marcello TonelliUNKNOWN Cholesterol and Recurrent Events (CARE) Trial Investigators
Mar 13, 2003·Kidney International·Guruprasad ManjunathMark J Sarnak
May 23, 2003·Journal of the American Society of Nephrology : JASN·Marcello TonelliUNKNOWN Cholesterol and Recurrent Events Trial Investigators
Jul 16, 2003·Annals of Internal Medicine·Andrew S LeveyUNKNOWN National Kidney Foundation
Jul 23, 2003·Journal of the American Society of Nephrology : JASN·Elke S SchaeffnerJ Michael Gaziano
Apr 22, 2004·Journal of the American Society of Nephrology : JASN·Daniel E WeinerMark J Sarnak
Sep 24, 2004·The New England Journal of Medicine·Alan S GoChi-yuan Hsu
Feb 8, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Vandana Menon, Mark J Sarnak
Jun 10, 2006·Journal of the American Society of Nephrology : JASN·Sabrina SandhuMarcello Tonelli
Nov 8, 2007·JAMA : the Journal of the American Medical Association·Josef CoreshAndrew S Levey

❮ Previous
Next ❯

Citations

Oct 12, 2012·International Urology and Nephrology·Agata Kujawa-SzewieczekGrzegorz Piecha
Apr 16, 2011·Clinical Journal of the American Society of Nephrology : CJASN·Winfried MärzUNKNOWN German Diabetes and Dialysis Study Investigators
Dec 15, 2011·Journal of Atherosclerosis and Thrombosis·Tetsuo ShojiUNKNOWN Committee of Renal and Peripheral Arteries, Japan Atherosclerosis Society
Feb 26, 2016·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Xiaole SuHong Zhang
Apr 2, 2013·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Marcin BarylskiUNKNOWN Lipid and Blood Pressure Meta-Analysis Collaboration Group
Sep 29, 2011·Metabolism: Clinical and Experimental·Sandra J HamiltonGerald F Watts
Feb 22, 2012·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Claudine T JurkovitzUNKNOWN KEEP Investigators
Dec 12, 2012·Public Health·A RobinsonM McKee
Mar 25, 2017·QJM : Monthly Journal of the Association of Physicians·C M Messow, C Isles
Dec 13, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Eman AwadHelga Stopper
May 13, 2011·Nephron. Clinical Practice·Mark S MacGregor, Maarten W Taal
Jun 1, 2014·The Cochrane Database of Systematic Reviews·Suetonia C PalmerGiovanni F M Strippoli
Nov 15, 2014·Journal of the American Society of Nephrology : JASN·Lisandro D ColantonioPaul Muntner
Apr 3, 2015·Clinical Journal of the American Society of Nephrology : CJASN·Rupert W MajorNigel J Brunskill
Jun 2, 2011·Nature Reviews. Nephrology·Vera Krane, Christoph Wanner
Sep 14, 2011·Nature Reviews. Nephrology·Suetonia C Palmer, Giovanni F M Strippoli
Oct 28, 2010·Expert Opinion on Pharmacotherapy·Anna GlubaMaciej Banach
Jun 5, 2012·Current Treatment Options in Cardiovascular Medicine·Cristina Karohl, Paolo Raggi
Aug 27, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·A OlyaeiE Lerma
Aug 16, 2019·Arteriosclerosis, Thrombosis, and Vascular Biology·José M ValdivielsoAlberto Ortiz
Feb 27, 2013·The Cochrane Database of Systematic Reviews·Fiona TaylorShah Ebrahim
Mar 10, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Cláudia Y SantosJessica Alber
Jun 22, 2019·Scientific Reports·Francisco Herrera-GómezF Javier Álvarez
Jan 20, 2011·Current Opinion in Nephrology and Hypertension·Sankar D NavaneethanGiovanni F M Strippoli
Jan 8, 2014·Postgraduate Medicine·Prakash C Deedwania

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.